Literature DB >> 35489781

Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.

Edna J Santos1, Matthew L Banks1, S Stevens Negus2.   

Abstract

Mu opioid receptor (MOR) agonists produce locomotor hyperactivity in mice as one sign of opioid-induced motor disruption. The goal of this study was to evaluate the degree of MOR efficacy required to produce this hyperactivity. Full dose-effect curves were determined for locomotor activation produced in male and female Institute of Cancer Research (ICR) mice by (1) eight different single-molecule opioids with high to low MOR efficacy and (2) a series of fixed-proportion fentanyl/naltrexone mixtures with high to low fentanyl proportions. Data from the mixtures were used to quantify the efficacy requirement for MOR agonist-induced hyperactivity relative to efficacy requirements determined previously for other MOR agonist effects. Specifically, efficacy requirement was quantified as the EP50 value, which is the "Effective Proportion" of fentanyl in a fentanyl/naltrexone mixture that produces a maximal effect equal to 50% of the maximal effect of fentanyl alone. Maximal hyperactivity produced by each drug and mixture in the present study correlated with previously published data for maximal stimulation of GTPɣS binding in MOR-expressing Chinese hamster ovary cells as an in vitro measure of relative efficacy. Additionally, the EP50 value for hyperactivity induced by fentanyl/naltrexone mixtures indicated that opioid-induced hyperactivity in mice has a relatively high efficacy requirement in comparison with some other MOR agonist effects, and in particular is higher than the efficacy requirement for thermal antinociception in mice or fentanyl discrimination in rats. Taken together, these data show that MOR agonist-induced hyperactivity in mice is efficacy dependent and requires relatively high levels of MOR agonist efficacy for its full expression. SIGNIFICANCE STATEMENT: Mu opioid receptor (MOR) agonist-induced hyperlocomotion in mice is dependent on the MOR efficacy of the agonist and requires a relatively high degree of efficacy for its full expression.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35489781      PMCID: PMC9341253          DOI: 10.1124/jpet.121.001045

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  47 in total

1.  Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.

Authors:  Morgane Thomsen; Brian S Fulton; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2013-08-31       Impact factor: 4.530

2.  Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone.

Authors:  Joanna C Jacob; Justin L Poklis; Hamid I Akbarali; Graeme Henderson; William L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

Review 3.  Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice.

Authors:  Heather Lyons Narver
Journal:  Lab Anim (NY)       Date:  2015-03       Impact factor: 12.625

4.  Brain mu and delta opioid receptors mediate different locomotor hyperactivity responses of the C57BL/6J mouse.

Authors:  G A Mickley; M A Mulvihill; M A Postler
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice.

Authors:  M Narita; Y Takahashi; K Takamori; M Funada; T Suzuki; M Misawa; H Nagase
Journal:  Jpn J Pharmacol       Date:  1993-05

6.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

7.  Morphine effects on mouse locomotor/exploratory activity: test dependency, test reliability, uni- and multi-variate analyses.

Authors:  G Loggi; G Laviola; E Alleva; F Chiarotti
Journal:  Pharmacol Biochem Behav       Date:  1991-04       Impact factor: 3.533

8.  Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice.

Authors:  Vladimir I Chefer; Brigitte L Kieffer; Toni S Shippenberg
Journal:  Eur J Neurosci       Date:  2003-10       Impact factor: 3.386

9.  A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects.

Authors:  Soumen Chakraborty; Jeffrey F DiBerto; Abdelfattah Faouzi; Sarah M Bernhard; Anna M Gutridge; Steven Ramsey; Yuchen Zhou; Davide Provasi; Nitin Nuthikattu; Rahul Jilakara; Melissa N F Nelson; Wesley B Asher; Shainnel O Eans; Lisa L Wilson; Satyanarayana M Chintala; Marta Filizola; Richard M van Rijn; Elyssa B Margolis; Bryan L Roth; Jay P McLaughlin; Tao Che; Dalibor Sames; Jonathan A Javitch; Susruta Majumdar
Journal:  J Med Chem       Date:  2021-09-10       Impact factor: 8.039

10.  Effects of the selective dopamine D3 receptor antagonist PG01037 on morphine-induced hyperactivity and antinociception in mice.

Authors:  Christian A Botz-Zapp; Stephanie L Foster; Desta M Pulley; Briana Hempel; Guo-Hua Bi; Zheng-Xiong Xi; Amy Hauck Newman; David Weinshenker; Daniel F Manvich
Journal:  Behav Brain Res       Date:  2021-08-02       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.